ES2475162T3 - Métodos para predecir la toxicidad cardíaca antes y después del tratamiento con inhibidores de tirosina cinasa - Google Patents
Métodos para predecir la toxicidad cardíaca antes y después del tratamiento con inhibidores de tirosina cinasa Download PDFInfo
- Publication number
- ES2475162T3 ES2475162T3 ES07757542.1T ES07757542T ES2475162T3 ES 2475162 T3 ES2475162 T3 ES 2475162T3 ES 07757542 T ES07757542 T ES 07757542T ES 2475162 T3 ES2475162 T3 ES 2475162T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- fatty acid
- tyrosine kinase
- acid oxidation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 31
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims abstract description 27
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims abstract description 25
- 206010048610 Cardiotoxicity Diseases 0.000 title claims abstract description 15
- 231100000259 cardiotoxicity Toxicity 0.000 title claims abstract description 15
- 230000007681 cardiovascular toxicity Effects 0.000 title claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 78
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 59
- 229930195729 fatty acid Natural products 0.000 claims abstract description 59
- 239000000194 fatty acid Substances 0.000 claims abstract description 59
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 57
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 40
- 230000003647 oxidation Effects 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract description 17
- 231100000331 toxic Toxicity 0.000 claims abstract description 11
- 230000002588 toxic effect Effects 0.000 claims abstract description 11
- 210000002064 heart cell Anatomy 0.000 claims abstract description 9
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract 2
- 150000002632 lipids Chemical class 0.000 claims description 33
- 229940022353 herceptin Drugs 0.000 claims description 20
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 19
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 102000020233 phosphotransferase Human genes 0.000 claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 230000037353 metabolic pathway Effects 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 description 50
- 230000014509 gene expression Effects 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- DYYZXRCFCVDSKD-UHFFFAOYSA-N N6,N6-dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 DYYZXRCFCVDSKD-UHFFFAOYSA-N 0.000 description 25
- 108010032363 ERRalpha estrogen-related receptor Proteins 0.000 description 23
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 20
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 19
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 19
- 210000002216 heart Anatomy 0.000 description 17
- 239000011575 calcium Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940043355 kinase inhibitor Drugs 0.000 description 14
- 230000004060 metabolic process Effects 0.000 description 14
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 101710192017 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 10
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 102100028704 Acetyl-CoA acetyltransferase, cytosolic Human genes 0.000 description 9
- 102000000584 Calmodulin Human genes 0.000 description 9
- 108010041952 Calmodulin Proteins 0.000 description 9
- 108091006146 Channels Proteins 0.000 description 9
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000017946 PGC-1 Human genes 0.000 description 8
- 108700038399 PGC-1 Proteins 0.000 description 8
- 102000004257 Potassium Channel Human genes 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 108020001213 potassium channel Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 7
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 6
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108010018763 Biotin carboxylase Proteins 0.000 description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 230000002407 ATP formation Effects 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 5
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 5
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 5
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 5
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 5
- 102000048238 Neuregulin-1 Human genes 0.000 description 5
- 108090000556 Neuregulin-1 Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 102000002932 Thiolase Human genes 0.000 description 5
- 108060008225 Thiolase Proteins 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229960004203 carnitine Drugs 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 108010052495 Calgranulin B Proteins 0.000 description 4
- 102100032050 Elongation of very long chain fatty acids protein 2 Human genes 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 108091006109 GTPases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000921368 Homo sapiens Elongation of very long chain fatty acids protein 2 Proteins 0.000 description 4
- 101001049828 Homo sapiens Potassium channel subfamily K member 6 Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 4
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 102100023203 Potassium channel subfamily K member 6 Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102100032420 Protein S100-A9 Human genes 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 102000018674 Sodium Channels Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000037149 energy metabolism Effects 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 101150055666 sox6 gene Proteins 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 102100038910 Alpha-enolase Human genes 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 3
- 102000016680 Dioxygenases Human genes 0.000 description 3
- 108010028143 Dioxygenases Proteins 0.000 description 3
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 3
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 3
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 3
- 102100025444 Gamma-butyrobetaine dioxygenase Human genes 0.000 description 3
- 102000009127 Glutaminase Human genes 0.000 description 3
- 108010073324 Glutaminase Proteins 0.000 description 3
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 3
- 101000911317 Homo sapiens Fatty acid-binding protein, liver Proteins 0.000 description 3
- 101000934612 Homo sapiens Gamma-butyrobetaine dioxygenase Proteins 0.000 description 3
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 3
- 101001047098 Homo sapiens Potassium voltage-gated channel subfamily G member 2 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102100022811 Potassium voltage-gated channel subfamily G member 2 Human genes 0.000 description 3
- 244000166071 Shorea robusta Species 0.000 description 3
- 235000015076 Shorea robusta Nutrition 0.000 description 3
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000008437 mitochondrial biogenesis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000004783 oxidative metabolism Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000003614 peroxisome proliferator Substances 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 230000015561 polyamine homeostasis Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 230000002336 repolarization Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 102000008538 voltage-gated sodium channel activity proteins Human genes 0.000 description 3
- 108040002416 voltage-gated sodium channel activity proteins Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002676 xenobiotic agent Substances 0.000 description 3
- 108700038202 AMP-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 description 2
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 2
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 2
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 2
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 108010059108 CD18 Antigens Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 101001066332 Caenorhabditis elegans Ras GTPase-activating protein gap-2 Proteins 0.000 description 2
- 101100501247 Caenorhabditis elegans elo-2 gene Proteins 0.000 description 2
- 101100501250 Caenorhabditis elegans elo-3 gene Proteins 0.000 description 2
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 2
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 2
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 2
- 102100036419 Calmodulin-like protein 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000011068 Cdc42 Human genes 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 101150073133 Cpt1a gene Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 102000004150 Flap endonucleases Human genes 0.000 description 2
- 108090000652 Flap endonucleases Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100023469 Glutathione S-transferase theta-2 Human genes 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102100028993 Hippocalcin-like protein 1 Human genes 0.000 description 2
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 description 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 2
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 2
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 2
- 101000888572 Homo sapiens Calcium-activated chloride channel regulator 1 Proteins 0.000 description 2
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 description 2
- 101000714353 Homo sapiens Calmodulin-like protein 5 Proteins 0.000 description 2
- 101000905982 Homo sapiens Glutathione S-transferase theta-2 Proteins 0.000 description 2
- 101000838883 Homo sapiens Hippocalcin-like protein 1 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 2
- 101000994790 Homo sapiens Ras GTPase-activating-like protein IQGAP2 Proteins 0.000 description 2
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 2
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 101000642613 Homo sapiens Sterol O-acyltransferase 2 Proteins 0.000 description 2
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 description 2
- 101000641959 Homo sapiens Villin-1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 2
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 2
- 101100126884 Mus musculus Camk4 gene Proteins 0.000 description 2
- 101100166829 Mus musculus Cenpk gene Proteins 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 108010077960 Neurocalcin Proteins 0.000 description 2
- 102000010751 Neurocalcin Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100034418 Ras GTPase-activating-like protein IQGAP2 Human genes 0.000 description 2
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000042463 Rho family Human genes 0.000 description 2
- 108091078243 Rho family Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101100501251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO3 gene Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 2
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101001083555 Sus scrofa Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 2
- 102000003618 TRPM4 Human genes 0.000 description 2
- 102100036502 Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase Human genes 0.000 description 2
- 108010039246 Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase Proteins 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 230000031154 cholesterol homeostasis Effects 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- -1 fatty acid hydroperoxides Chemical class 0.000 description 2
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 201000008186 generalized epilepsy with febrile seizures plus Diseases 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007372 neural signaling Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000037359 steroid metabolism Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 150000004669 very long chain fatty acids Chemical class 0.000 description 2
- 230000022814 xenobiotic metabolic process Effects 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- 102100035905 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Human genes 0.000 description 1
- 108010020180 2,4-dienoyl-CoA reductase Proteins 0.000 description 1
- 102000009724 2,4-dienoyl-CoA reductase Human genes 0.000 description 1
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phospho-D-glyceric acid Chemical compound OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 description 1
- FVZXYJDGVYLMDB-UHFFFAOYSA-N 3-pyridin-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CC=N1 FVZXYJDGVYLMDB-UHFFFAOYSA-N 0.000 description 1
- 102100040078 A-kinase anchor protein 5 Human genes 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100032921 ATP-dependent 6-phosphofructokinase, liver type Human genes 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 102100031460 Advillin Human genes 0.000 description 1
- 102000018757 Apolipoprotein L1 Human genes 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 108010052469 Apolipoprotein L1 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101100214824 Caenorhabditis elegans abhd-5.2 gene Proteins 0.000 description 1
- 101100064707 Caenorhabditis elegans eef-2 gene Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000030060 Congenital non-bullous ichthyosiform erythroderma Diseases 0.000 description 1
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100022206 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Human genes 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 101710088791 Elongation factor 2 Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 1
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 208000006562 Glycogen Storage Disease Type VII Diseases 0.000 description 1
- 208000031926 Glycogen storage disease due to muscle phosphofructokinase deficiency Diseases 0.000 description 1
- 102100023281 Guanine nucleotide-binding protein subunit beta-5 Human genes 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
- 108010050763 Hippocalcin Proteins 0.000 description 1
- 101000929840 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Proteins 0.000 description 1
- 101000841262 Homo sapiens 3-ketoacyl-CoA thiolase Proteins 0.000 description 1
- 101000890614 Homo sapiens A-kinase anchor protein 5 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 101000730830 Homo sapiens ATP-dependent 6-phosphofructokinase, liver type Proteins 0.000 description 1
- 101000729999 Homo sapiens Advillin Proteins 0.000 description 1
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 1
- 101000900394 Homo sapiens Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Proteins 0.000 description 1
- 101000866749 Homo sapiens Elongation factor 2 Proteins 0.000 description 1
- 101000755879 Homo sapiens Fructose-bisphosphate aldolase A Proteins 0.000 description 1
- 101000829985 Homo sapiens Guanine nucleotide-binding protein subunit beta-5 Proteins 0.000 description 1
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 description 1
- 101001053578 Homo sapiens IQ domain-containing protein H Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000979596 Homo sapiens NF-kappa-B-repressing factor Proteins 0.000 description 1
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 1
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000614798 Homo sapiens cAMP-dependent protein kinase type II-alpha regulatory subunit Proteins 0.000 description 1
- 101000614806 Homo sapiens cAMP-dependent protein kinase type II-beta regulatory subunit Proteins 0.000 description 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100024433 IQ domain-containing protein H Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000042189 MAGUK family Human genes 0.000 description 1
- 108091077533 MAGUK family Proteins 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 206010068836 Metabolic myopathy Diseases 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100054965 Mus musculus Adipoq gene Proteins 0.000 description 1
- 101100342155 Mus musculus Prkg1 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100023379 NF-kappa-B-repressing factor Human genes 0.000 description 1
- 102100021310 Neurexin-3 Human genes 0.000 description 1
- 102100028669 Neuron-specific calcium-binding protein hippocalcin Human genes 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000011244 Nuclear receptor coactivator Human genes 0.000 description 1
- 108050001461 Nuclear receptor coactivator Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 102100031166 Peripheral plasma membrane protein CASK Human genes 0.000 description 1
- 208000020547 Peroxisomal disease Diseases 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 101710175177 Very-long-chain 3-oxoacyl-CoA reductase Proteins 0.000 description 1
- 102100037438 Very-long-chain 3-oxoacyl-CoA reductase Human genes 0.000 description 1
- 101710187138 Very-long-chain 3-oxoacyl-CoA reductase-A Proteins 0.000 description 1
- 101710187143 Very-long-chain 3-oxoacyl-CoA reductase-B Proteins 0.000 description 1
- 102100033419 Villin-1 Human genes 0.000 description 1
- 101000979710 Xenopus laevis Neuronal calcium sensor 1 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 102100021204 cAMP-dependent protein kinase type II-alpha regulatory subunit Human genes 0.000 description 1
- 102100021205 cAMP-dependent protein kinase type II-beta regulatory subunit Human genes 0.000 description 1
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 1
- 108010025267 calcium-dependent protein kinase Proteins 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108020004067 estrogen-related receptors Proteins 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 201000009339 glycogen storage disease VII Diseases 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 102000045173 human VIL1 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 108010008386 malonyl-Coa reductase Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000026326 mitochondrial transport Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000004802 pathophysiological signal Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 210000003538 post-synaptic density Anatomy 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- DEUWDIBQYKIQOA-ACRIIGJESA-N sodium;(2r)-2-amino-4-[4-[(z)-c-[[(3s)-1-[(r)-carboxy-(4-hydroxyphenyl)methyl]-2-oxoazetidin-3-yl]carbamoyl]-n-hydroxycarbonimidoyl]phenoxy]butanoic acid Chemical compound [Na+].C1=CC(OCC[C@@H](N)C(O)=O)=CC=C1C(=N\O)\C(=O)N[C@@H]1C(=O)N([C@@H](C(O)=O)C=2C=CC(O)=CC=2)C1 DEUWDIBQYKIQOA-ACRIIGJESA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005657 synaptic vesicle exocytosis Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010052178 teleocalcin Proteins 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77709606P | 2006-02-27 | 2006-02-27 | |
| US777096P | 2006-02-27 | ||
| US82123006P | 2006-08-02 | 2006-08-02 | |
| US821230P | 2006-08-02 | ||
| US82737206P | 2006-09-28 | 2006-09-28 | |
| US827372P | 2006-09-28 | ||
| US82834506P | 2006-10-05 | 2006-10-05 | |
| US828345P | 2006-10-05 | ||
| US86773606P | 2006-11-29 | 2006-11-29 | |
| US867736P | 2006-11-29 | ||
| PCT/US2007/062871 WO2007101191A2 (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2475162T3 true ES2475162T3 (es) | 2014-07-10 |
Family
ID=38459790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07757542.1T Active ES2475162T3 (es) | 2006-02-27 | 2007-02-27 | Métodos para predecir la toxicidad cardíaca antes y después del tratamiento con inhibidores de tirosina cinasa |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8709738B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1996939B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5539653B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101390625B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101438155B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007220094B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2643846A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2475162T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193715A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ571465A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007101191A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
| WO2015027171A1 (en) * | 2013-08-23 | 2015-02-26 | Quintiles Transnational Corporation | Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway |
| CA2944181C (en) | 2014-03-27 | 2019-09-17 | Salk Institute For Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| EP3262157A4 (en) * | 2015-02-27 | 2018-12-05 | Salk Institute for Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| EP3485001A4 (en) | 2016-05-25 | 2020-08-12 | Salk Institute for Biological Studies | COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF ORGANOIDS AND THE MODELING OF DISEASES |
| JP7032723B2 (ja) * | 2017-07-21 | 2022-03-09 | 公立大学法人福島県立医科大学 | 薬剤の心毒性評価方法及びそのための試薬又はキット |
| US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
| TWI711458B (zh) * | 2019-07-08 | 2020-12-01 | 大江生醫股份有限公司 | 植物發酵物及其製備方法與用於胃臟保健的用途 |
| KR102493664B1 (ko) | 2020-01-29 | 2023-02-01 | 한국화학연구원 | 심장 독성 예측 모델링 시스템 및 모델링 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| DK1438420T3 (da) | 2001-09-24 | 2010-01-18 | Lipomics Technologies Inc | Fremgangsmåder til anvendelse af kvantitative lipid-metablom-data |
| SG152922A1 (en) * | 2002-11-04 | 2009-06-29 | Univ California | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body |
| PL1668152T3 (pl) * | 2003-08-28 | 2009-06-30 | Ipsogen | Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka |
-
2007
- 2007-02-27 NZ NZ571465A patent/NZ571465A/en not_active IP Right Cessation
- 2007-02-27 WO PCT/US2007/062871 patent/WO2007101191A2/en not_active Ceased
- 2007-02-27 CN CN2007800136974A patent/CN101438155B/zh not_active Expired - Fee Related
- 2007-02-27 JP JP2008556587A patent/JP5539653B2/ja not_active Expired - Fee Related
- 2007-02-27 AU AU2007220094A patent/AU2007220094B2/en not_active Ceased
- 2007-02-27 CN CN2013101368247A patent/CN103217520A/zh active Pending
- 2007-02-27 ES ES07757542.1T patent/ES2475162T3/es active Active
- 2007-02-27 KR KR1020087023650A patent/KR101390625B1/ko not_active Expired - Fee Related
- 2007-02-27 CA CA002643846A patent/CA2643846A1/en not_active Abandoned
- 2007-02-27 NZ NZ594178A patent/NZ594178A/xx not_active IP Right Cessation
- 2007-02-27 EP EP07757542.1A patent/EP1996939B1/en not_active Not-in-force
- 2007-02-27 US US12/280,893 patent/US8709738B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 IL IL193715A patent/IL193715A/en not_active IP Right Cessation
-
2012
- 2012-12-26 JP JP2012282502A patent/JP2013063090A/ja active Pending
-
2013
- 2013-04-05 US US13/857,591 patent/US20130288285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186910A1 (en) | 2009-07-23 |
| CN101438155B (zh) | 2013-04-24 |
| WO2007101191A2 (en) | 2007-09-07 |
| IL193715A0 (en) | 2009-05-04 |
| EP1996939A4 (en) | 2009-07-15 |
| IL193715A (en) | 2014-06-30 |
| JP2013063090A (ja) | 2013-04-11 |
| AU2007220094A1 (en) | 2007-09-07 |
| EP1996939B1 (en) | 2014-03-26 |
| JP5539653B2 (ja) | 2014-07-02 |
| US8709738B2 (en) | 2014-04-29 |
| US20130288285A1 (en) | 2013-10-31 |
| JP2009533017A (ja) | 2009-09-17 |
| AU2007220094B2 (en) | 2013-12-05 |
| EP1996939A2 (en) | 2008-12-03 |
| CA2643846A1 (en) | 2007-09-07 |
| CN101438155A (zh) | 2009-05-20 |
| CN103217520A (zh) | 2013-07-24 |
| NZ571465A (en) | 2011-09-30 |
| NZ594178A (en) | 2013-02-22 |
| KR20090008194A (ko) | 2009-01-21 |
| WO2007101191A3 (en) | 2007-12-13 |
| KR101390625B1 (ko) | 2014-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2475162T3 (es) | Métodos para predecir la toxicidad cardíaca antes y después del tratamiento con inhibidores de tirosina cinasa | |
| Zhenyukh et al. | High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation | |
| Herbert et al. | Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells | |
| Barazzoni et al. | Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)–nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction | |
| Cao et al. | Effects of exercise on AMPK signaling and downstream components to PI3K in rat with type 2 diabetes | |
| Kim et al. | TAK1 is a central mediator of NOD2 signaling in epidermal cells | |
| Shen et al. | Effects of conjugated linoleic acid (CLA) on fat accumulation, activity, and proteomics analysis in Caenorhabditis elegans | |
| Prasad et al. | WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells | |
| Gemmink et al. | Dissociation of intramyocellular lipid storage and insulin resistance in trained athletes and type 2 diabetes patients; involvement of perilipin 5? | |
| Camacho et al. | Energy state of the liver during short-term and exhaustive exercise in C57BL/6J mice | |
| WO2008016730A2 (en) | Compositions and methods for reducing cellular fat | |
| Dutta et al. | Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy | |
| Pietropaoli et al. | Glutamate excitotoxicity linked to spermine oxidase overexpression | |
| Ohnuki et al. | Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2‐adrenoceptor stimulation | |
| RU2362565C2 (ru) | Применение s1p | |
| Yamada et al. | AMPK activation, eEF2 inactivation, and reduced protein synthesis in the cerebral cortex of hibernating chipmunks | |
| Liu et al. | 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3 | |
| Livshits et al. | Effect of short-term hyperglycemia on protein kinase C alpha activation in human erythrocytes | |
| Tsameret et al. | Effect of early vs. late time-restricted high-fat feeding on circadian metabolism and weight loss in obese mice | |
| Gonzalez et al. | Effects of aging on cardiac and skeletal muscle AMPK activity: basal activity, allosteric activation, and response to in vivo hypoxemia in mice | |
| Lee et al. | Muscle-specific activation of Ca2+/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice | |
| Singh et al. | Proteomic identification of 14-3-3ζ as an adapter for IGF-1 and Akt/GSK-3β signaling and survival of renal mesangial cells | |
| Martinez-Canton et al. | CaMKII protein expression and phosphorylation in human skeletal muscle by immunoblotting: Isoform specificity | |
| Rider et al. | Phosphorylation of translation factors in response to anoxia in turtles, Trachemys scripta elegans: role of the AMP-activated protein kinase and target of rapamycin signalling pathways | |
| Karyo et al. | Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3 |